CRISM Therapeutics Secures FDA Orphan Drug Designation for Brain Cancer Treatment
Key Insights
CRISM Therapeutics received FDA Orphan Drug Designation for its irinotecan-ChemoSeed (search) programme, covering all high-grade gliomas (search) including Grade III and IV tumors.
The designation provides seven years of market exclusivity upon approval, tax credits for clinical trials, and exemption from FDA application fees.
Combined with the UK's Innovation Passport, the regulatory milestones position the company for coordinated global development of its localized chemotherapy delivery platform.
CRISM Therapeutics Corporation (search) received a significant regulatory boost as the U.S. Food and Drug Administration granted Orphan Drug Designation to its irinotecan-ChemoSeed (search) programme for treating malignant glioma (search). The designation covers all high-grade gliomas (search), including Grade III and IV tumors, representing a broader scope than the company's original request limited to glioblastoma (search).
The clinical-stage drug delivery company's shares jumped 12% to 13.4p following the announcement, reflecting investor confidence in the regulatory milestone's commercial implications.
Regulatory Benefits and Market Exclusivity
Orphan Drug Designation targets treatments for rare diseases affecting fewer than 200,000 people in the United States. The status provides substantial commercial incentives including seven years of U.S. market exclusivity upon product approval, tax credits for qualified clinical trials, and exemption from FDA application fees.
"Receiving Orphan Drug Designation from the FDA is a strong validation of the potential of irinotecan-ChemoSeed (search)," said Professor Chris McConville, Chief Scientific Officer of CRISM Therapeutics. "From a strategic perspective, this designation enhances the regulatory profile and potential commercial attractiveness of the programme and supports our strategy of advancing differentiated oncology assets that address significant unmet medical needs."
Global Regulatory Strategy
The FDA milestone follows CRISM's Innovation Passport granted by the UK's Medicines and Healthcare products Regulatory Agency under its Innovative Licensing and Access Pathway. This dual regulatory recognition creates coordinated development opportunities across major jurisdictions as the company advances its registration-grade Phase 2 clinical trial in surgically resectable glioblastoma (search).
The company believes these regulatory designations position irinotecan-ChemoSeed (search) for potential participation in international collaborative review programmes such as Project Orbis, led by the FDA, which enables participating regulators to review promising cancer treatments concurrently.
ChemoSeed Technology Platform
CRISM's ChemoSeed (search) technology represents an innovative approach to cancer treatment through localized and sustained delivery of chemotherapy drugs. The implantable device can be placed directly into the tumor or resection margin following tumor removal, directing therapeutic concentrations of chemotherapy drugs to deep-seated tumor tissue.
For glioblastoma (search) treatment, ChemoSeeds can be implanted during surgery, bypassing the blood-brain barrier that prevents other treatments from reaching the tumor effectively. Glioblastoma ranks among the most aggressive brain cancers, with median survival typically measured in months.
Clinical Development Progress
The company is currently conducting a registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed (search) in surgically resectable glioblastoma (search). McConville noted that the combination of regulatory designations positions the programme well for constructive regulatory engagement as the trial progresses.
The coordinated regulatory approach across the UK and United States is designed to position ChemoSeed (search) for accelerated development, regulatory review, and commercial readiness across key global markets, supporting the company's strategy of advancing differentiated oncology assets for significant unmet medical needs.